Bortezomib-based induction therapy followed by intravenous busulfan–melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma-Reference-Cited by-同舟云学术

Bortezomib-based induction therapy followed by intravenous busulfan–melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

Published:2014-07-17 Issue:2 Volume:56 Page:415-419
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Blanes Margarita,González José D.,Lahuerta Juan J.,Ribas Paz,Lorenzo Ignacio,Boluda Blanca,Sanz Miguel A.,de la Rubia Javier

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.922182

Reference40 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

3. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

4. The role of complete response in multiple myeloma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome;Leukemia & Lymphoma;2022-11-23

2. Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma;Hematological Oncology;2020-07-29

3. Brain glucose metabolism in patients with newly diagnosed multiple myeloma significantly decreases after high-dose chemotherapy followed by autologous stem cell transplantation;Nuclear Medicine Communications;2020-03

4. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial;The Lancet Haematology;2019-05

5. Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma;Annals of Hematology;2019-03-16